Lipid & CV Risk Decision Tool
Enter patient data below and generate a personalized clinical summary
ℹ︎ This tool runs entirely offline — no data is transmitted. Works in any browser. Double-click the .html file to open.
Paste Epic SmartPhrase
Optional — auto-fills fields below
Epic SmartPhrase template
AGE: @AGE@ SEX: @LEGALSEX@ GFR: @LLABV(egfr)@ TC: @LLABV(Chol)@ LDL: @LLABV(LDL)@ HDL: @LLABV(HDL)@ TG: @LLABV(Trig)@ LPA: @LLABV(LIPOPROTEIN)@ APOB: @LLABV(APOLIPOPROTE)@ HSCRP: @LLABV(HSCRP)@ A1c: @LLABV(hgba1c)@ ACR: @LLABV(MICROALBCRH)@ BMI: @LASTBMI(1)@ Last BP: @LASTBP(1)@ BP Medications: @CERMSG(82376:)@ Statin: @CERMSG(987871:)@ Smoking: @TOBHXP@ Zip: @CTYSTZIP@ DM: @CERMSG(985502:;585500024:,0,1,1)@
How to use:
① Paste Epic SmartPhrase output below
② Click Parse & Calculate
③ Review the populated inputs and decision summary
Fields can also be entered manually without a SmartPhrase. PREVENT is race-free and requires age, sex, total cholesterol, HDL-C, systolic BP, eGFR, and the clinical toggles below.
Fields can also be entered manually without a SmartPhrase. PREVENT is race-free and requires age, sex, total cholesterol, HDL-C, systolic BP, eGFR, and the clinical toggles below.
Clinical ASCVD status
Primary prevention
Secondary — ASCVD high risk
Secondary — ASCVD very high risk *
* Very high risk = ≥2 major ASCVD events or 1 major event + ≥2 high-risk conditions (age ≥65, HeFH, DM, HTN, HF, current smoking, prior revascularization, LDL-C ≥100 on maximal statin + ezetimibe)
Risk-enhancing factors
Select all that apply
None
HIV
CKD stage 3–4
Familial hypercholesterolemia
Family history premature ASCVD
Chronic inflammation (RA/lupus)
South Asian / Filipino ancestry
Preeclampsia / premature menopause
CAC 1–99 and <75th percentile
CAC ≥100 or ≥75th percentile
CV risk calculator inputs
PREVENT
Required · validated range 15–150
Required · validated range 18.5–39.9
Optional PREVENT predictor · ≥30 flags CKD
No
Yes
No
Yes
No
Yes
No
Yes
Current lipid-lowering regimen
Select all medications being taken, then select the current dose. PREVENT specifically requires statin status.
Lipid panel
mg/dL
Validated range 130–320; values below 130 use 130
Non-HDL-C —
TC/HDL ratio —
VLDL-C (TG/5) —
Calculated automatically from entries above
Extended biomarkers
Risk reclassifiers
nmol/L — Low <75, Intermediate 75–<125, High ≥125
mg/dL — Optimal <90, Moderate 90–129, High ≥130
mg/L — ASCVD risk enhancer ≥2; repeat/evaluate if ≥10
Decision Summary
—
Biomarker interpretation
Clinical recommendations
Patient communication
Patient message (editable boilerplate)
Offline
This tool reflects the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline (JACC, March 13, 2026). Aspirin guidance reflects 2022 USPSTF recommendations. This is a clinical decision-support aid for physician use only. Clinical judgment and shared decision-making are required. Not a substitute for full clinical assessment. Questions: me@gennadygelman.com